PF-Atlas › Treatments › MSC-Derived Extracellular Vesicles

MSC-Derived Extracellular Vesicles

EV cargo (miR-29, let-7d) delivers anti-fibrotic miRNA without cell engraftment risk

Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Phase I
Evidence level
Level 3 (Phase I)
Mechanism class
EV cargo (miR-29, let-7d) delivers anti-fibrotic miRNA without cell engraftment risk
Timeline
3-5 years
Risk profile
Medium
Developer
Multiple
Key researchers
Multiple

Overview

miR-29 depleted in IPF lung. EVs from young MSCs reduce fibrosis markers. Better safety than cell therapy.

How MSC-Derived Extracellular Vesicles fits into IPF treatment

MSC-Derived Extracellular Vesicles is classified as Level 3 (Phase I) at the Phase I stage. Explore how it compares to other options and where it sits in the development pipeline:

MSC-Derived Extracellular Vesicles drug profileEV cargo (miR-29, let-7d) delivers anti-fibrotic miRNA without cell engraftment riskClinical trialsDrug pipelineResearch

Other IPF treatments

Nerandomilast / JascaydInhaled Treprostinil / TyvasoAdmilparant / BMS-986278Rentosertib / ISM001-055AI Knowledge GraphuPAR-CAR-T Senolytic Immunotherapy
Medical disclaimer. This page summarizes published research and PF-Atlas model output about MSC-Derived Extracellular Vesicles for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.